tiprankstipranks
Trending News
More News >

Madrigal Pharmaceuticals price target raised to $458 from $441 at UBS

UBS raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $458 from $441 and keeps a Buy rating on the shares. Madrigal’s Q1 is supportive of a major 2025 for metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue